These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 30842489)

  • 1. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
    Jiang L; Guo F; Liu X; Li X; Qin Q; Shu P; Li Y; Wang Y
    Sci Rep; 2019 Mar; 9(1):3705. PubMed ID: 30842489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.
    Li X; Lian Z; Wang S; Xing L; Yu J
    Cancer Lett; 2018 Apr; 418():1-9. PubMed ID: 29309815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.
    Suda K; Rozeboom L; Furugaki K; Yu H; Melnick MAC; Ellison K; Rivard CJ; Politi K; Mitsudomi T; Hirsch FR
    Biomed Res Int; 2017; 2017():7694202. PubMed ID: 29119113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients 
with Advanced EGFR Positive NSCLC and Its Relationship with the 
Therapeutic Efficacy of EGFR-TKIs].
    Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
    Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
    Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
    Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
    Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
    Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
    Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.
    Lin K; Cheng J; Yang T; Li Y; Zhu B
    Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):95-101. PubMed ID: 25998384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.
    Li N; Zuo R; He Y; Gong W; Wang Y; Chen L; Luo Y; Zhang C; Liu Z; Chen P; Guo H
    Cell Death Dis; 2024 Aug; 15(8):555. PubMed ID: 39090096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
    Watanabe S; Hayashi H; Haratani K; Shimizu S; Tanizaki J; Sakai K; Kawakami H; Yonesaka K; Tsurutani J; Togashi Y; Nishio K; Ito A; Nakagawa K
    Cancer Sci; 2019 Jan; 110(1):52-60. PubMed ID: 30390416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.